Drugs / Remaxa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06183242 | May 2023 → Sep 2024 | intrahepatic cholestasis | POLYSAN Scientific & Technological Pharmaceutical Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REMAXA | “The study drug REMAXA® enteric-coated tablets is a hybrid drug which contains the same active metabolites as REMAXOL, i.e. inosine, methionine, nicotinamide, and succinic acid.” NCT06183242 ↗ |
| Modality | Other / unclassified | “The study drug REMAXA® enteric-coated tablets is a hybrid drug” NCT06183242 ↗ |